If you have ever browsed a peptide website, you have read the sentence: "For research use only. Not for human consumption." It sits at the bottom of the product page, under paragraphs describing what the compound does to appetite, metabolism, or tissue repair. A lot of buyers read that line as a legal boundary. It is not one.
Under federal law, what a product is depends on what the seller intends it for, and intent is not established by a disclaimer. The regulation that governs this, 21 CFR 201.128, defines "intended uses" as the objective intent of whoever is responsible for the labeling. That intent can be shown by labeling claims, advertising, the design of the product, or the circumstances of how it is distributed. [1] In other words, the FDA reads the whole page, not just the fine print.
The agency has spelled this out directly. In a March 31, 2026 warning letter to an online seller, the FDA wrote that "[d]espite statements on your product labeling marketing your products for 'Research Use Only,' and 'not intended for human consumption, medical use, or veterinary use,' evidence obtained from your website establishes that your products are intended to be drugs for human use." The evidence it cited was the seller's own product copy about appetite suppression, insulin sensitivity, and fat oxidation. The agency also treated the bacteriostatic water sold alongside the vials as part of the picture, since selling the two together signals they are meant to be mixed and injected. [2]
Once a product is a drug in that sense, it is an unapproved new drug unless there is an approved application for it, and shipping it in interstate commerce violates sections 301(d) and 505(a) of the Federal Food, Drug, and Cosmetic Act. That is the legal machinery behind the wave of warning letters peptide sellers have received since 2024. [3]
Why this matters for anyone reading a label rather than writing one: the disclaimer is not a quality claim. It does not mean the vial was tested, that the contents match the sticker, that the dose is what it says, or that anything sterile happened in the room where it was filled. It is a phrase intended to shift risk toward the buyer, and the FDA does not treat it as protecting the seller either.
Where Peppies stands. We are not neutral on this, and we say so. We argue that a legal, tested, prescription pathway through licensed pharmacies is safer for people than an unregulated market of anonymous vials, and we disclose our interest plainly: Peppies is a for-profit venture that would benefit only from a future legal market. We do not sell peptides. On the science we take no position. These compounds have not been evaluated by the FDA for safety or effectiveness, we make no efficacy claims, and nothing here is medical advice. The regulatory question is live and unsettled, and the advisory committee meeting on July 23 and 24 is one step in it. [4]
Sources
- eCFR, 21 CFR 201.128, Meaning of "intended uses"
- FDA Warning Letter, Gram Peptides, MARCS-CMS 721806, March 31, 2026
- FDA Warning Letter, Pinnacle Professional Research dba Pinnacle Peptides, December 12, 2025
- Regulations.gov, docket FDA-2025-N-6895
The moment that counts comes later. When the FDA opens the public comment window that carries legal weight, we'll tell you. Get notified →